Hemostemix Inc., of Calgary Alberta, closed its nonbrokered private placement of units for gross proceeds of $266,500. The offering consisted of the issuance of about 26.6 million units at a price of 1 cent each. A unit consists of one common share in the capital of the company and one common share purchase warrant, with each full warrant entitling the holder to acquire one share at a price of 5 cents for a period of 12 months from the closing of the offering,
Inimmune Inc., of Missoula, Mont., raised $22 million in series A funding. It was the firm’s first outside investment. The round was led by Two Bear Capital, the founder and managing partner of which, Michael Goguen, has joined the company’s board. Inimmune is working on treatments leveraging the immune system, especially novel adjuvants.
Inventiva SA, of Daix, France, priced its IPO on Nasdaq by way of a capital increase of about 7.4 million new ordinary shares, consisting of a public offering of about that many shares in the form of American depositary shares, each representing one ordinary share. Proceeds are expected to total about $107.7 million. Shares (NASDAQ:IVA) closed July 10 at $13.42, down 98 cents. Also, the company resumed trading of its ordinary shares on Euronext Paris.
Nicox SA, of Sophia Antipolis, France, sold its remaining stake in Visufarma BV, of Amsterdam, to a subsidiary of the main shareholder, GHO Capital, for €5 million (US$5.6 million). The stake consisted of shares in the U.K. holding company of Visufarma and loan notes granted by the firm. Nicox transferred its European and international commercial entities and certain assets and rights to Visufarma in August 2016.
Ocumension Therapeutics Ltd., of Shanghai, launched its IPO on the Stock Exchange of Hong Kong. Ocumension plans to offer about 105.9 million shares priced at HK$14.66 (US$1.89) each and will trade under the stock code 1477.HK. Morgan Stanley, Goldman Sachs and UBS are acting as joint global coordinators, bookrunners and lead managers.